High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements
📧 Sign up to get email alerts when something new happens for High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial update evaluating epcoritamab in combination with dose-adjusted EPOCH-R for aggressive B-cell non-Hodgkin lymphoma;…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia [Phase 2]
A Phase 2 clinical trial evaluating ascorbic acid with chemotherapy for relapsed/refractory lymphoma, clonal cytopenia of undetermined signi…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene [Phase 1, Phase 2]
An NCI-sponsored clinical trial is evaluating the safety of CX-5461 (Pidnarulex) in lymphomas with MYC alterations, including Burkitt lympho…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas [Phase 2, Phase 3]
A Phase 2/Phase 3 trial is evaluating adding venetoclax to standard chemotherapy for high-grade B-cell lymphomas, including diffuse large B-…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells [Phase 2]
Phase 2 study investigating fecal microbiota transplant to remodel gut microbiota in patients with relapsed/refractory diffuse large B-cell …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma [Phase 1]
Phase 1 trial evaluating polatuzumab vedotin with chemotherapy, with or without glofitamab, for untreated aggressive large B-cell lymphoma. …
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma [Phase 1]
Phase 1 clinical trial update for tegavivint in relapsed or refractory diffuse large B-cell lymphoma, with ongoing recruitment.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial update reports ongoing Phase 1/2 testing of the combination epcoritamab plus ibrutinib for relapsed or refractory aggres…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia [Phase 2]
Phase 2 clinical trial update describing a combination chemotherapy regimen for relapsed or refractory acute lymphoblastic leukemia, lymphob…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Ongoing Phase 2 trial evaluating nivolumab in combination with DA-REPOCH chemotherapy for aggressive B-cell non-Hodgkin lymphomas, including…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma [Phase 1]
An early-phase study evaluating the combination of parsaclisib with standard therapy in newly diagnosed, high-risk diffuse large B-cell lymp…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating loncastuximab tesirine and rituximab followed by DA-EPOCH-R for high-risk diffuse large B-cell lymphoma. Recruitmen…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating Tafasitamab and Lenalidomide followed by Tafasitamab and ICE as salvage therapy for transplant-elig…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment [Phase 2]
This SWOG Cancer Research Network Phase 2 trial is evaluating adding drugs to standard therapy for large B-cell lymphoma that has returned o…
-
CLINICAL_TRIALS research · 2025-06-13Clinical Trial Update: Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma [Phase 1]
Phase 1 clinical trial evaluating C402-CD19-CAR for relapsed or refractory B-cell lymphomas is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-01-29Clinical Trial Update: Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma [Phase 1]
A Phase 1 trial evaluating the combination of chemotherapy with TAK-659 as front-line treatment for high-risk diffuse large B-cell lymphoma,…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas [Phase 2]
Phase 2 trial evaluating nivolumab with or without varlilumab in relapsed or refractory aggressive B-cell lymphomas, including multiple DLBC…
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
Phase 3 clinical trial update investigating zanubrutinib with rituximab and/or combination chemotherapy for newly diagnosed aggressive B-cel…
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
Phase 3 trial update evaluating orelabrutinib with rituximab and combination chemotherapy for newly diagnosed aggressive B-cell non-Hodgkin …